Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daunorubicin and cytarabine liposome (Jazz Pharmaceuticals plc, 043c8a)
- Development stage
- Phase 4
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CPX-351 (Vyxeos) is a liposomal encapsulation of the antineoplastic agents cytarabine and daunorubicin in a fixed 5:1 molar ratio. This specific ratio was identified in vitro to maximize synergistic killing of leukemia cells. The liposomal delivery system optimizes the pharmacokinetics of the two drugs, providing a prolonged plasma half-life and preferential accumulation and uptake within the bone marrow, thereby increasing exposure to malignant progenitor cells while reducing systemic toxicity. It was originally developed by Celator Pharmaceuticals (acquired by Jazz Pharmaceuticals) and is FDA-approved for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
- Brand names
- Vyxeos
- Other names
- liposomal cytarabine and daunorubicincytarabine/daunorubicin liposome
02
Targets
POLA1 (DNA polymerase alpha)DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on daunorubicin and cytarabine liposome (Jazz Pharmaceuticals plc, 043c8a).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daunorubicin and cytarabine liposome (Jazz Pharmaceuticals plc, 043c8a).